Summary
This clinical trial is testing whether a targeted cancer treatment called zanzalintinib works better than everolimus, an approved treatment for some neuroendocrine tumours (NETs), in people whose cancer has grown, spread, or cannot be removed with surgery.
Neuroendocrine tumours are a type of cancer that can develop in the pancreas or other parts of the body, such as the digestive system or lungs.
Who may be able to join?
You may be eligible if:
- you are aged 18 years or older
- you have a well-differentiated neuroendocrine tumour that started in the pancreas or another organ
- your cancer is locally advanced, unresectable or metastatic
- you have received previous treatment for your NET
- your cancer has shown signs of worsening or growing within the last 12 months
Some people will not be eligible, including those who have previously received certain targeted treatments, such as VEGFR-targeting drugs or mTOR inhibitors, or who have received some recent cancer treatments.
What treatment will participants receive?
Participants are randomly assigned (by chance) to receive either:
- Zanzalintinib (the investigational treatment), or
- Everolimus (an approved treatment for some neuroendocrine tumours).
Researchers want to determine whether zanzalintinib can control neuroendocrine tumours for longer or more effectively than everolimus, while also evaluating safety and side effects.
Conditions
This trial is treating people with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors of pancreatic origin or extra-pancreatic origin.